Navigation Links
InterMune to Present at Citi's 4th Annual Biotech Day
Date:3/30/2009

BRISBANE, Calif., March 30 /PRNewswire-FirstCall/ -- InterMune, Inc. (Nasdaq: ITMN) today announced that Daniel G. Welch, Chairman, Chief Executive Officer and President of InterMune, will present at Citi's 4th Annual Biotech Day in New York City on April 1, 2009 at 10:40 a.m. EDT.

To access a live audio webcast of the presentation, investors and other interested parties may log on to the investor relations page of InterMune's corporate website at www.intermune.com. The company recommends logging on to the site 15 minutes prior to the start of the presentation in order to register or download any necessary software.

About InterMune

InterMune is a biotechnology company focused on the research, development and commercialization of innovative therapies in pulmonology and hepatology. InterMune has a pipeline portfolio addressing idiopathic pulmonary fibrosis (IPF) and hepatitis C virus (HCV) infections. The pulmonology portfolio includes the Phase 3 program, CAPACITY, which is evaluating pirfenidone as a possible therapeutic candidate for the treatment of patients with IPF, RECAP, an open-label extension study from CAPACITY, and a research program focused on pirfenidone analog ITMN-520. The hepatology portfolio includes the HCV protease inhibitor compound ITMN-191 (referred to as R7227 at Roche) in Phase 1b, a second-generation HCV protease inhibitor research program, and a research program evaluating a new target in hepatology. For additional information about InterMune and its R&D pipeline, please visit www.intermune.com.


'/>"/>
SOURCE InterMune, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1

Related biology technology :

1. InterMune to Present Abstracts on HCV Protease Inhibitor ITMN-191 and HCV Development Program at the EASL Meeting
2. InterMune Reports Fourth Quarter and Full Year 2008 Financial Results and Business Highlights
3. InterMune to Release Fourth Quarter, Full Year 2008 Financial Results on February 26
4. InterMune Announces Issuance of U.S. Patent for ITMN-191
5. InterMune Announces Pricing of Public Offering of 3,500,000 Shares of Common Stock
6. InterMune Reports Results of Two Phase 3 CAPACITY Studies of Pirfenidone in IPF
7. InterMune to Present at J.P. Morgan Healthcare Conference
8. InterMune to Present at Deutsche Bank Biotech Boston Confab
9. InterMune Reports Third Quarter 2008 Financial Results and Business Highlights
10. InterMune to Release Third Quarter 2008 Financial Results on November 6
11. InterMune Reports Japanese Regulatory Approval of Pirfenidone in IPF
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/29/2016)... New York , April 29, 2016 /PRNewswire/ ... report published by Transparency Market Research "Separation Systems ... Size, Share, Growth, Trends, and Forecast 2015 - ... was valued at US$ 10,665.5 Mn in 2014 ... of 6.8% from 2015 to 2023 to reach ...
(Date:4/29/2016)... 2016 Elekta is pleased to ... its industry-leading treatment planning software, is available for clinical ... version 5.11 provides significant performance speed enhancements ... up to four times faster than in previous versions ... gold standard Monte Carlo algorithm, ...
(Date:4/28/2016)... ... April 28, 2016 , ... Next week ... talk on its first-in-class technologies for tissue stem cell counting and expansion to ... Biology to Reprogramming & CRISPR-based Genome Engineering in Burlington, Massachusetts. , The attention ...
(Date:4/27/2016)... ... ... Shimadzu Scientific Instruments (SSI) will be showcasing a broad ... Expo. Shimadzu’s high-performance instruments enable laboratories to test cannabis products for potency, moisture, ... booth 1021 to learn how Shimadzu’s instruments can help improve QA/QC testing, peak ...
Breaking Biology Technology:
(Date:4/14/2016)... AVIV, Israel , April 14, 2016 ... Behavioral Authentication and Malware Detection, today announced the appointment ... already assumed the new role. Goldwerger,s leadership ... BioCatch, on the heels of the deployment of its ... addition, BioCatch,s behavioral biometric technology, which discerns unique cognitive ...
(Date:3/31/2016)... RATON, Florida , March 31, 2016 ... LEGX ) ("LegacyXChange" or the "Company") ... for potential users of its soon to be launched ... video ( https://www.youtube.com/channel/UCyTLBzmZogV1y2D6bDkBX5g ) will also provide ... the use of DNA technology to an industry that ...
(Date:3/29/2016)... 2016 LegacyXChange, Inc. (OTC: ... SelectaDNA/CSI Protect are pleased to announce our successful effort ... variety of writing instruments, ensuring athletes signatures against counterfeiting ... from athletes on LegacyXChange will be assured of ongoing ... Bill Bollander , CEO states, "By ...
Breaking Biology News(10 mins):